U.S. Markets closed

PAVmed Inc. (PAVM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
8.21+0.13 (+1.61%)
At close: 4:00PM EDT
Sign in to post a message.
  • T
    Tom
    Christmas is arriving early this year. Congratulations to all shareholders on your special dividend to be formally announced. Our Super Bowl winning management team has done it again. Good Luck to All.
  • R
    Robert
    https://www.cmlviz.com/stocks/PAVM/news/b/2021/09/22/lucid-diagnostics-files-for-ipo
    Lucid Diagnostics Inc Says Intend to Apply to List Common Stock on Nasdaq Under Symbol “lucd”.
    Lucid Diagnostics Inc Says Cantor and Canaccord Genuity Are Among Underwriters to Ipo.
    Lucid Diagnostics Inc Says Pavmed Inc Currently Owns About 72.6% of Co's Outstanding Common Stock, and Controlling Stockholder.
    Bullish
  • W
    Wally
    Smart move… Interesting.,, State Street Corp reports 43.73% increase in ownership of PAVM / PAVmed Inc

    2021-08-16 - State Street Corp has filed a 13F-HR form disclosing ownership of 1,195,419 shares of PAVmed Inc (US:PAVM) with total holdings valued at $7,651,000 USD as of 2021-06-30. State Street Corp had filed a previous 13F-HR/A on 2021-07-09 disclosing 831,703 shares of PAVmed Inc at a value of $3,693,000 USD. This represents a change in shares of 43.73 percent and a change in value of 107.18 percent during the quarter.
  • T
    Tom
  • W
    Wally
    Analyst Upgraded today…Good Luck to All…
    450
    * Pavmed Inc : Ascendiant Capital Markets raises target price to $10 from $9.50
  • k
    kevin
    Over 6% of the float is short as of Aug 31.

    If we get to $12 I think we will start to see some capitulation which should add support to the price.
  • R
    Robert
    PAVmed Inc (PAVM) - Lucid Diagnostics Inc. Files for Ipo of Up to $57.5 Million - Sec Filing.
    Bullish
  • Z
    Ziggy
    As shareholders of PAVM, do we still get 1 share of LUCD for every 5 shares that we already own? I remember reading that here several weeks back. That would be sweet if true!
  • F
    Faust
    I think 25% bump is justified based on Lucid IPO
    Bullish
  • p
    pace long
    I love this company
  • C
    Conner
    just cashed out 2000 shares. thanks for the five g’s in profit.
  • B
    Barbara
    Up to this point common shareholders have been able to loosely share the appreciation of value with larger shareholders and/or upper management. Now, with the proposed spinoff of Lucid the balance moves markedly in favor of management/controlling shareholders. The claim that cash from a Lucid IPO will provide financial comfort to regular shareholders is "financial pie in the sky." The only way present common shareholders might really share would be: (1) a direct ratio distribution of Lucid shares or (2) stock rights for the purchase of Lucid shares. Some actions such as these would show management is keeping faith with shareholders and not just using us to only enrich themselves.
  • D
    Dr. Oddz
    Think about it, 7 million in volume yesterday with no news. Something going on here behind the scenes. This isnt retail.
  • T
    Tom
    Very informative CC. IMO PAVM shareholders will be reviving a special dividend of 1 share of Lucid for every 5 shares owned of PAVM. Lucid’s IPO price will be anywhere in-between 20-25 pps depending on market conditions.
    Bullish
  • D
    David
    The Lucid IPO only gives PAVM about 40 million, then it has sold off the company to the public! It should have commercialized the test Lucid developed instead of making quick money selling off Lucid. So the company sells off a third of it’s business and the stock goes up? Something is wrong here!
  • L
    Lenny
    @ John Shorting stocks is a way of making money and it’s okay when you find a company that has no purpose or the ones that the Management team has no morals and all they want to do is take people’s money like NKLA did, but shorting a company that has a purpose and is trying to help people not develop esophageal cancer is not only detrimental to people’s health but quite possibly detrimental to your pocket. If it’s true that you studied economics you’d know that PAVmed will eventually become a bigger business because it is bringing a solution to a serious problem at a much more affordable price than an endoscopy and the shares will follow it’s success. GLTA longs
  • T
    Tom
    WOW! 0 debt…enough cash on hand to carry operations through 2023, centers only have to perform 2 procedures a week to be profitable. Europe and Asia coming on line. Super Bowl winning management team.
    Bullish
  • A
    Alana
    Analyst Upgraded today…Good Luck to All…
    450
    * Pavmed Inc : Ascendiant Capital Markets raises target price to $10 from $9.50
  • A
    Alana
    …… Business Update Highlights

    Lucid began testing patients referred by primary care physicians ("PCPs") at three Lucid Test Centers in the Phoenix metropolitan area. Patients with chronic heartburn, also known as gastroesophageal reflux disease ("GERD"), who are referred to the centers are now undergoing an esophageal precancer procedure, performed by Lucid-employed clinical personnel, using Lucid’s EsoCheck® Cell Collection Device ("EsoCheck") to collect surface esophageal cells for its EsoGuard® Esophageal Test ("EsoGuard").

    EsoGuard testing accelerated as the company continued to see good results from its initial engagements with gastroenterologists. Lucid performed 202 EsoGuard tests in the second quarter representing a 110% increase sequentially compared to an upward revised 96 tests performed in the first quarter.

    Lucid entered into a definitive agreement with UpScriptHealth ("UpScript"), a leading, nationwide, direct-to-consumer telemedicine company for UpScript to support Lucid’s upcoming EsoGuard Telemedicine Program by providing a Lucid-branded web-based telemedicine platform for patients with GERD to request video evaluation by a physician and, if clinically indicated, referred to a Lucid Test Center for EsoGuard testing.

    Lucid received CE Mark certification for EsoCheck, and completed CE Mark self-certification for EsoGuard, indicating both may be marketed in CE Mark European countries.

    Lucid continued the process of transferring EsoCheck manufacturing to Coastline International Inc., a high-volume manufacturer based in San Diego, CA with production facilities in Mexico, by the end of 2021, which will increase EsoCheck manufacturing capacity up to one million devices per year.

    Lucid held a successful advisory board meeting with medical directors of major insurers which provided positive feedback and indicated good alignment with its strategic approach, including expectations for the portfolio of clinical utility and healthcare economic data which would be needed to secure payment and coverage

    Lucid began enrolling patients at European sites for its international multi-center clinical studies, to support a PMA application for FDA IVD registration of EsoGuard on samples collected using EsoCheck.

    PAVmed launch of a new subsidiary, digital health company, Veris Health, which acquired Oncodisc Inc., a digital health company with groundbreaking tools to improve personalized cancer care through remote patient monitoring. Oncodisc’s core technologies include the first intelligent implantable vascular access port with biologic sensors and wireless communication, combined with an oncologist-designed remote digital healthcare platform. Veris has launched both device and software design efforts and is engaging third party device and software partners. Veris has also initiated discussions for a potential collaboration with a large global software company.

    PAVmed’s new CarpX national sales manager began work in June and has begun the reboot of CarpX initial commercialization efforts. Multiple cadaver training sessions have been scheduled or completed and CarpX cases have been scheduled.